0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anthera Pharmaceuticals
Its shares trade under the ticker ANTH. It has been listed since 2 March 2010. In the fiscal year to 31 December 2017, it reported a net loss of $16.9m. At that date it held total assets of $3.7m and shareholders' equity of −$5.5m.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. The company is headquartered in Hayward, California. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Mar 2010
- Employees
- 21
- Website
- anthera.com ↗
Leadership
Pay as last reported
- Mr. Paul TruexExecutive Chairman of the Board, since 2004$1.4m
- Mr. J. Craig ThompsonPresident, Chief Executive Officer, Director, since 2016$888,377
- Ms. May LiuSenior Vice President - Finance and Administration, Principal Accounting Officer$592,612
- Mr. Brent FurseIndependent Director
- Dr. Christopher HenneyIndependent Director, since 2005
- Mr. Brian MuellerIndependent Director
- Dr. Philip SagerIndependent Director
- Mr. David ThompsonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong and experienced management team, capable of driving the company's growth strategy.
- Promising portfolio of novel drug candidates with potential for significant market impact.
- Supporting intellectual property rights and patents provide a competitive advantage.
- Well-established partnerships and collaborations with key industry players, enhancing research and development capabilities.
Weaknesses
- Limited financial resources and high dependency on external funding for research and development activities.
- Relatively small market presence compared to established pharmaceutical companies.
- Some drug candidates are still in early stages of development, increasing the risk of failure or delays.
- Lack of diversification in the product pipeline, making the company vulnerable to setbacks in specific programs.
Opportunities
- Growing demand for innovative therapeutic solutions in the pharmaceutical industry.
- Expansion into new geographical markets and strategic collaborations with international partners.
- Advances in technology and research methodologies provide opportunities for accelerated drug development.
- Potential for market exclusivity and premium pricing for successful drug candidates.
Threats
- Intense competition from established pharmaceutical companies with greater resources and market presence.
- Stringent regulatory requirements and challenges in obtaining necessary approvals for drugs.
- Uncertainty associated with the outcome of clinical trials and potential adverse effects of drug candidates.
- Rapidly evolving market dynamics and changes in healthcare policies may impact market access and pricing.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.